ESMO 2020 | QOLIXANE: QoL and efficacy data in 1L pancreatic cancer

Thorsten Goetze, MD, Institute of Clinical Cancer Research, Frankfurt, Germany,talks about data coming from the QOLIXANE-PARAGON study (NCT02691052) – a prospective, non-interventional, multicenter sub-study of the PARAGON-registry, conducted in Germany. Dr Götze discusses real life quality of life and efficacy data in 1L pancreatic cancer and showed that the time to deterioration of quality of life is short in patients with metastatic pancreatic cancer, but it could be used as a predictor of patient outcome in this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).